Why Is DANAHER CORP (DHR) Stock Down Today?

Danaher (DHR) stock fell 10.99% to $179.01 on July 21, 2026, marking its worst single-day decline in over 30 years. The sharp drop followed the company's Q2 2026 earnings report, which failed to fully satisfy investor expectations despite beating revenue and earnings estimates. The stock opened with a 9.5% gap down from the prior close and traded down to $165.75 before closing at $179.01.

What Happened

Danaher reported Q2 2026 adjusted earnings per share of $1.94, exceeding the $1.84 estimate, and revenue of $6.27 billion, surpassing the $6.18 billion forecast. The company raised its 2026 adjusted EPS guidance to $8.45, $8.60 and highlighted strength in its Life Sciences segment. However, investors appeared unimpressed with the overall results, which were described as underwhelming by some analysts. The stock’s decline was exacerbated by concerns over slower-than-expected growth in non-respiratory segments and risks related to bioprocess timing. Mizuho analyst Jared Holz noted that the selloff represented Danaher’s worst trading day in 25 years.

What The Data Shows

The intraday session showed a sharp decline, with volume reaching 23.0 million shares, more than five times the 3-month average. The stock opened at $181.99 and hit a low of $165.75 before recovering slightly. The 52-week range is $160.93 to $242.80, and the stock is now trading near the lower end of that range. Danaher’s fundamentals include a market cap of $137.0 billion, a P/E ratio of 37.6, and a revenue increase of 4.0% trailing twelve months. Despite these metrics, the stock’s beta of 0.82 and dividend yield of 0.83% did not provide a buffer against the selloff.

What To Watch

Danaher’s next key event is its Q3 2026 earnings report, which will be closely watched for signs of recovery in its core segments. Investors should also monitor coverage breadth and sentiment shifts, particularly in the coming weeks.